# About rx Epitalon: An Independent Editorial Digest of the AEDG Pineal Tetrapeptide Literature

> About this site: rx Epitalon is an independent editorial digest of the peer-reviewed Epitalon and Epithalamin literature — a textile-layered reading of the Khavinson St. Petersburg program record. Not a clinic, not a vendor.

A publication, not a practice — a hand-bound digest of what the Khavinson program and its Western replicators have actually measured.

## What this site is

rx Epitalon is an independent editorial project that publishes summaries of the peer-reviewed research literature on Epitalon — the synthetic AEDG tetrapeptide designed by Vladimir Khavinson's St. Petersburg group [1][14]. The work is editorial commentary on publicly available science. The site is not a clinic. It does not employ clinicians and it does not provide medical advice. It does not manufacture, sell, or distribute any product. It is not affiliated with any peptide vendor or any pharmaceutical company.

## What the 'rx' in the name means — and does not mean

The 'rx' prefix in the domain name is editorial framing — a position the publisher occupies relative to the literature, signalling the careful, citation-anchored register of the reading. It is not a claim about the site's services. This site does not write prescriptions. It does not consult with patients. It does not represent any prescribing clinician. The 'rx' is a typographic mark of editorial seriousness — the dossier reads the literature with the care a clinical reference would receive — not an indicator of clinical practice.

## Editorial method

The dossier is built from PubMed-indexed English-language sources where possible — the seminal 2003 Khavinson telomerase paper in *Bulletin of Experimental Biology and Medicine* [1], the 2025 Al-dulaimi independent replication in *Biogerontology* [2], the 2020 Khavinson histone-binding mechanism paper in *Molecules* [3], the Anisimov cancer-model series in *International Journal of Cancer* and *Cancer Letters* [4][5][8], the Korkushko elderly-melatonin cohort work [11][12], the 2002 Khavinson 'Peptides and Ageing' monograph in *Neuro Endocrinology Letters* [14], and the 2025 Araj consolidation review in *International Journal of Molecular Sciences* [15]. Russian-language sources are not cited directly; their contents are referenced via the Khavinson 2002 and Araj 2025 reviews.

## What is honest about this literature

The Epitalon literature has unusual geography. Most positive in vivo and cohort data originate from a single research program — the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology [14]. A large fraction of the supporting work is Russian-language and not well indexed in Western databases. Validated pharmacokinetic data and modern regulatory-grade toxicology packages are absent from the peer-reviewed literature, as the 2025 Araj review explicitly notes [15]. Independent Western replication of the lifespan and cohort-mortality findings is limited. A 2025 cell-line replication has reset the modern reading of the telomerase work [2]. None of this makes the literature worthless — it makes it specific, citable, and bounded.

## What this site does not claim

rx Epitalon does not claim Epitalon is safe for human use, effective for any indication, or appropriate for any reader's personal circumstances. It does not endorse the compound. It does not recommend doses. It does not sell, distribute, or refer to any vendor. It does not host advertising for peptide products. The site exists to make the peer-reviewed literature legible to a reader who wants to understand what the published studies actually measured — no more, no less.

---

A textile-layered editorial digest of the Khavinson pineal tetrapeptide literature — Epitalon and Epithalon read as one molecule, two spellings, and twenty-five years of mostly-Russian record, with the Western trial gap named.